Investment Strategy
Focus: Within the broader healthcare market, we focus our investments on medical technologies including medical devices, diagnostics, drug delivery, and digital health. We back both first-time and experienced founders, who value our participation as well our capital.
Stage: We are typically the first institutional investor and support companies through early product and clinical development and often through the regulatory process. We make our first investment at the seed through series B stage, based on when the risk of translation from pre-clinical to clinical is at its lowest. We are life cycle investors and continue to support our portfolio companies through to exit.
Capital Efficiency: We invest in companies that are able to demonstrate early and meaningful clinical value with minimum capital invested and preserve the most appropriate exit opportunity.
Therapeutic Indications: While we are agnostic to therapeutic indication, we invest in companies developing products that address large, global markets and where there is significant unmet clinical need. We particularly like therapeutic devices that significantly improve patient outcomes and diagnostics that fundamentally change the course of therapeutic intervention.
